Non-Compliance at Chinese Heparin Manufacturer

Recommendation
16-18 September 2025
Barcelona, Spain
Organisation of a GMP-compliant Site Change
A Non-Compliance Report has been issued to a Chinese heparin manufacturer after an inspection conducted on October 2018. During this inspection performed by the Italian Health Authority on behalf of EMA & EDQM, several violations of GMP were identified.
The company located in Sichuan manufactures crude heparin. In total, 24 GMP deficiencies were observed of which 7 were classified as major. Those major deficiencies were identified in the following areas:
- Risk of contamination
- Buildings and facilities
- Equipment
- Storage of starting material
- Manufacturing process
- Materials management
- Traceability of starting material
- Recovery of solvents
In 2014 already, the US American health authority FDA had issued a Form 483 due to deviations observed during an inspection at this facility. The recent European report now recommends to prohibit the supply of crude heparin from this facility but not to recall already shipped batches. The inspection outcome will also have consequences on the CEPs concerned by EDQM.
The Non-Compliance Report (EudraGMDP No 51022) can be read on the EMA website for Non-Compliance Reports.
Related GMP News
02.07.2025EFPIA Report on Current Inspections
18.06.2025FDA Warning Letter with Supplier Qualification Observations
11.06.2025Root Cause Investigations criticised at EU Company
21.05.2025More FDA Warning Letters citing Quality Oversight
21.05.2025New Version of GMP Auditors Handbook available
21.05.2025FDA: more unannounced Inspections also outside the US